Costs associatd with candidemia in a hospital setting

P and T

Volumn 31, Issue 10, 2006, Pages

  Gagne, Joshua J ^a   Breithart, Ross E ^c   Maio, Vittorio ^a   Horn, David L ^a   Hartmann, Christine W ^a   Swanson, Robert ^b   Goldfarb, Neil I ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; COST OF ILLNESS; DIAGNOSIS RELATED GROUP; FEMALE; FUNGEMIA; HEALTH CARE COST; HOSPITAL COST; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PHARMACY; TERTIARY HEALTH CARE; URBAN AREA;

EID: 33750485011     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990: National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-1251.
2. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999;29:239-244.
3. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-1530.
4. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005;41:1232-1239.
5. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-3645.
6. Rentz AM, Halpern MT, Bowden R The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-788.
7. Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34.
8. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-547.
9. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-1177.
10. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, et al. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: Emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005;26:548-552.
11. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial bloodstream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998;31:327-332.
12. Wright WL, Wenzel RP. Nosocomial Candida: Epidemiology, transmission, and prevention. Infect Dis Clin North Am 1997;11:411-425.
13. Trick WE, Fridkin SK, Edwards JR, et al. National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-630.
14. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999;29:1164-1170.
15. Peabody JW, Luck J, Jain S, et al. Assessing the accuracy of administrative data in health information systems. Med Care 2004;42:1066-1072.
16. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-2645.
17. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model. Clin Infect Dis 1997;24:1068-1078.
18. Ray WA. Policy and program analysis using administrative data-bases. Ann Intern Med 1997;127(8 Part 2):712-718.
19. Golan Y, Wolf MP, Pauker SG, et al. Empirical anti-Candida therapy among selected patients in the intensive care unit: A cost-effectiveness analysis. Ann Intern Med 2005;143(12):857-869.